OPT 6.10% 43.5¢ opthea limited

From the clip:“We are excited to test sozinibercept in large P3...

  1. 107 Posts.
    lightbulb Created with Sketch. 88

    From the clip:
    “We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“

    To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.

    I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
(20min delay)
Last
43.5¢
Change
0.025(6.10%)
Mkt cap ! $529.3M
Open High Low Value Volume
42.0¢ 44.0¢ 42.0¢ $473.3K 1.112M

Buyers (Bids)

No. Vol. Price($)
12 39542 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
43.5¢ 55503 4
View Market Depth
Last trade - 12.58pm 29/07/2024 (20 minute delay) ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.